Company Overview and News

47
Royal Gold: A Streamer Bucking The Trend

2018-06-07 seekingalpha
The company has some of the strongest gross margins of all companies in the S&P 500.
SAND SSL GOOS NGD SDDXF OKSWF NGDAF SNXZF NGD RGLD OR GORO OSKGF RGL GSC

12
Teranga Gold - I'm Still Bullish

2018-05-16 seekingalpha
In my opinion, the company is heading in the right direction: Sabodala performs well and the Wahgnion gold project in Burkina Faso is entering the development stage.
KGI KGI.DB.A RGORF KGI.DB EDVMF GRY GOLD RRS GPHYF GOLD TGZ TGZ EDVVF EVR KL EDV GSC

24
Royal Gold's (RGLD) CEO Tony Jensen on Q3 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Good day. And welcome to the Royal Gold Fiscal 2018 Third Quarter Conference Call. All participants will be in listen-only mode [Operator Instructions]. After today’s presentation, there will be an opportunity to ask questions [Operator Instructions]. Please note this event is being recorded.
RGLD CTGO NGD NGDAF NGD RGL GSC

7
Golden Star Resources' (GSS) CEO Sam Coetzer on Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Golden Star Resources Ltd (NYSEMKT:GSS) Q1 2018 Earnings Conference Call May 3, 2018 9:30 AM ET
GSS GSC

0
Duketon Mining extends strike length at Golden Star in Eastern Yilgarn province

2018-04-19 proactiveinvestors.com.au
Duketon Mining Ltd (ASX:DKM) has released assay results for the Golden Star prospect in Western Australia, boosting management’s confidence that it is on to a larger gold zone.
DKM RRL SBM RGRNF GSC

8
Should Value Investors Pick Golden Star (GSS) Stock Now?

2018-04-11 zacks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process.
GSS GSC

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to TSX:GSC / Golden Star on message board site Silicon Investor.

Golden Star Resources Ltd. - A Potenial Ten Bagger GSCN - General Scanning
Geoscience Corp (GSCI)